Ascidian Therapeutics

1 known investors

Ascidian Therapeutics develops RNA exon editing technology that rewrites RNA by editing and replacing human exons, aiming to create a class of medicines addressing the underlying genetic causes of disease. Its platform targets diseases not addressed by DNA-based gene editing, offering post-transcriptional editing that produces full-length functional proteins.